A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors

Junichiro Ohira, MD<sup>a,b</sup>,∗, Michi Kawamoto, MD<sup>a</sup>, Yoshio Sugino, MD, PhD<sup>c</sup>, Nobuo Kohara, MD, PhD<sup>a</sup>

Abstract
Introduction: Immune-related adverse events (ir-AEs) are increasingly becoming a concern, as immune checkpoint inhibitors (ICIs) are used more frequently. Herein, we present a case of fulminant cytokine release syndrome (CRS) complicated by dermatomyositis after the combination therapy with ICIs.

Patient concerns: A 70-year-old male developed dermatomyositis during the course of treatment with two ICIs, nivolumab and ipilimumab. He was treated by steroid pulse therapy, but the effect was limited. Afterwards, he had acute-onset high fever, hypotension, respiratory failure, impaired consciousness, renal failure, and coagulation abnormality at the same time. CRP, creatinine kinase (CK), D-dimer, and ferritin levels were considerably elevated: CRP, 24 mg/dL; CK, 40,500 U/L; D-dimer, 290 μg/mL; ferritin, 329,000 ng/mL.

Diagnosis: CRS induced by ICI combination therapy.

Interventions: Given that high fever and elevated CRP level indicated potential sepsis, an antibiotic was used until the confirmation of negative blood cultures. All the simultaneous acute symptoms were supposed to be CRS. He was admitted to the intensive care unit (ICU), and temporary intubation and hemodialysis were needed. Immunosuppressive therapy was reinforced by mycophenolate mofetil together with steroid, and plasma exchange was performed for the elimination of abnormal proteins.

Outcomes: The patient’s clinical symptoms and laboratory parameters gradually improved and he was discharged from the ICU in a month.

Conclusion: Fulminant CRS can be induced by ICI combination therapy. As the initial symptoms of CRS resemble sepsis, it is important to consider CRS as a differential diagnosis and to initiate immunosuppressive therapy early when needed. In steroid-resistant cases, early introduction of other immunosuppressive therapy and plasma exchange can be effective.

Abbreviations: γ-GTP = γ-glutamyltransferase, ALP = alkaline phosphatase, ALT = alanine transaminase, APTT = activated partial thromboplastin time, ASPS = alveolar soft part sarcoma, AST = aspartate aminotransferase, BUN = blood urea nitrogen, CAR-T = chimeric antigen receptor engineered T, CFPM = cefepime, CHDF = continuous hemodiafiltration, CK = creatinine kinase, CRP = C reactive protein, CRS = cytokine release syndrome, CT = computed tomography, CTLA-4 = cytotoxic T-lymphocyte associated protein 4, HD = hemodialysis, HL = hodgkin lymphoma, HLH = hemophagocytic lymphohistiocytosis, ICIs = immune checkpoint inhibitors, IL = interleukin, INF-γ = interferon-γ, ir-AEs = immune-related adverse events, IVIG = intravenous immunoglobulin, LDH = lactate dehydrogenase, MEMP = meropenem, MMF = mycophenolate mofetil, mPSL = methylprednisolone, MSAs = myositis specific autoantibodies, PD-1 = programmed cell death protein 1, PE = plasma exchange, PF = purpura fulminans, PSL = prednisolone, PT-INR = prothrombin time-international normalized ratio, sIL-2R = soluble interleukin-2 receptor, TIF1-γ = transcriptional intermediary factor 1-γ, TM = thrombomodulin, TNFα = tumor necrosis factor-α, TTP = thrombotic thrombocytopenic purpura, VCM = vancomycin.

Keywords: cytokine release syndrome, dermatomyositis, immune checkpoint inhibitors, immune-related adverse events

Editor: N/A.

The authors have no conflicts of interest to disclose.

© 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Ohira J, Kawamoto M, Sugino Y, Kohara N. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine 2020;99:15(e19741).

Received: 2 August 2019 / Received in final form: 7 January 2020 / Accepted: 4 March 2020
http://dx.doi.org/10.1097/MD.0000000000019741
1. Introduction

Immune checkpoint inhibitors (ICIs) have emerged as a novel class of anti-cancer agents. ICIs include the programmed cell death protein 1 (PD-1), its ligand (PD-L1), and the cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors. The basic mechanism of action of these drugs is to release the brakes of immune regulation and to restore anti-cancer immune response.\(^\text{1,2}\) It has been recently demonstrated that combination therapy with nivolumab (a PD-1 inhibitor) and ipilimumab (a CTLA-4 inhibitor) prolonged survival better than standard chemotherapy for the treatment of metastatic renal cell carcinoma.\(^\text{3}\) However, various immune-related adverse events (ir-AEs) have been reported to occur during such treatment.\(^\text{1,2}\) The incidence of ir-AEs in melanoma patients was higher during combination therapy than during monotherapy with either nivolumab or ipilimumab\(^\text{4}\), and thus ir-AEs are of greater concern in the combination use of ICIs. Neuromuscular ir-AEs sometimes occur and myositis is known to be one of the most frequent ones.\(^\text{5}\)

Cytokine release syndrome (CRS) is a condition of immune system hyperactivation typically reported in leukemia patients after chimeric antigen receptor engineered T (CAR-T) cell therapy.\(^\text{6–8}\) Although uncommon, severe CRS can occur after the administration of ICIs.\(^\text{9–13}\) In this report, we describe a patient with fulminant CRS complicated by dermatomyositis after ICI combination therapy, who temporarily needed intubation and hemodialysis, but recovered after immunosuppressive therapy and plasma exchange followed by intravenous immunoglobulin (IVIg) therapy.

2. Case report

An appropriate written informed consent for publication was obtained from the patient and his family.

2.1. Patient background before admission

A chest X-ray during a routine medical examination of a 70-year-old male on September 2018 revealed a large tumor in the right lung field. Truncal contrast-enhanced computed tomography (CT) for further evaluation showed multiple tumors in mediastinal lymph nodes, lung, left kidney, para-aortic lymph nodes, and vertebral bodies, as well as in the right thoracic wall, which had been identified in the chest X-ray (Fig. 1A (A1, A2)). The left renal biopsy confirmed the diagnosis of renal cell carcinoma with multiple metastases. It was evaluated as clinical stage 4, T4N1M1 in accordance with TNM classification of Malignant Tumor 8th edition (Union for International Cancer Control, Geneva, Switzerland) and pathological grade 4.\(^\text{14}\) As a surgical operation was not applicable, a combination of the ICIs, nivolumab and ipilimumab, was chosen as the initial treatment (Fig. 2).\(^\text{3}\) On the following day after the administration of both drugs, erythema appeared on his dorsal hands and gradually spread to all extremities and body trunk on a daily basis. As the application of steroid ointment was not effective, 30 mg oral prednisolone was administered three weeks after the appearance of erythema. On the same day, nivolumab and ipilimumab, was chosen as the initial treatment (Fig. 2).\(^\text{3}\) The left renal biopsy confirmed the diagnosis of renal cell carcinoma with multiple metastases. It was evaluated as clinical stage 4, T4N1M1 in accordance with TNM classification of Malignant Tumor 8th edition (Union for International Cancer Control, Geneva, Switzerland) and pathological grade 4.\(^\text{14}\) As a surgical operation was not applicable, a combination of the ICIs, nivolumab and ipilimumab, was chosen as the initial treatment (Fig. 2).\(^\text{3}\) On the following day after the administration of both drugs, erythema appeared on his dorsal hands and gradually spread to all extremities and body trunk on a daily basis. As the application of steroid ointment was not effective, 30 mg oral prednisolone was administered three weeks after the appearance of erythema. On the same day, nivolumab and ipilimumab were administered for the second time, because erythema was considered to be the only side effect of the first administration. Two days after the second administration, the patient began to

---

**Figure 1.** (A) Truncal contrast-enhanced computed tomography at the diagnosis of multiple tumors. (A1) Tumors of mediastinal lymph nodes and the right thoracic wall. (A2) Tumors of the left kidney and para-aortic lymph nodes. (B) Short-tau inversion recovery MRI showing broad hyperintensity in left upper limb muscles. (B1) Coronal section. (B2) Axial section.
have difficulty in elevating his upper limbs and standing up from a squatting position. Although erythema started to improve and oral prednisolone was reduced to 20mg, he was referred to our Neurology Department by the urologist due to developing muscle weakness 1 week after the second administration. On physical examination, the patient did not have respiratory distress and was alert. He had Gottron sign, shawl sign, and mild erythema on the back, abdomen, and face. Neurological examination revealed proximal limb muscle and truncal weakness without easy fatigability. He had no gait disturbance but had difficulty in sitting up from the supine position. Cranial nerve abnormalities including impairment of ocular movement, ptosis, dysartrhia, or dysphasia were not observed. All other neurological findings were normal. The blood test revealed marked elevation of creatinine kinase (CK, 17,386 U/L) (Table 1) and positive for anti-Mi-2 (>150; normal range, 0–52) and anti-transcriptional intermediary factor 1-γ (anti-TIF1-γ) antibodies (50; normal range, 0–31). The patient had a lower titer of anti-Mi-2 antibody (124) and was negative for anti-TIF1-γ antibody before the administration of the ICIs. Anti-aminoacyl tRNA synthetase antibodies and an acetylcholine receptor antibody were negative. Electromyography showed active myopathic changes in the left biceps, right deltoid, and left paraspinal muscles. Low-frequency repetitive stimulation demonstrated no decrement in the left
ulnar, facial, and accessory nerves. Magnetic resonance imaging of the left proximal upper limb showed edema and inflammation (Fig. 1B). Therefore, the patient was diagnosed with dermatomyositis, which most likely was an ir-AE (Grade 3, according to the Common Terminology Criteria for Adverse Events [version 5.0]) induced by the two ICIs, and admitted to our Neurology Department.

2.2. Clinical course after admission

As his muscle weakness was progressing even after oral administration of prednisolone at 20 to 30 mg, he was treated with intravenous pulse therapy of 500 mg methylprednisolone for 3 days from the admission day (day 1), followed by 30 mg oral prednisolone (Fig. 2). Both ICIs were discontinued. The reduction in CK level was limited to mild, and muscle weakness remained at the same level. In the evening of day 5, the patient had an acute episode of high fever (39°C) and started shivering. Systolic blood pressure dropped to 100 mmHg from 150 mmHg. As the blood test revealed elevated white blood cell count (27,800/μL) and C-reactive protein level (8.89 mg/dL), sepsis was suspected, and intravenous administration of cefepime was initiated. Next morning (day 6), the patient had pale extremities, respiratory failure, anuria due to acute renal failure, and mildly impaired consciousness, in addition to high fever. The laboratory tests showed considerable elevation of CRP, CK, D-dimer, and ferritin levels, which indicated disseminated intravascular coagulation and cytokine storm (Table 1). Arterial blood showed lactic acidosis (lactate level, 6.2 mmol/L) and hypoxemia (PaO2, 57.4 mmHg). The patient’s symptoms were getting worse hourly, and

| Table 1 |
| --- |
| Laboratory parameters on days 1, 6, 16, and around day 30. |
| **Day 1** | **Day 6** | **Day 16** | **∼Day 30** | Normal range |
| --- | --- | --- | --- | --- |
| Complete blood count | 10,000 | 23,900 | 8,500 | 3,900–9,800 (μL) |
| White blood cell | 15.7 | 16.5 | 8.9 | 7.5 |
| Hemoglobin | 48.6 | 51.0 | 26.7 | 24.2 |
| Platelets | 71 | 29.6 | 17.8 | 16.9 |
| Biochemistry | 13.4–17.6 (g/dL) | 13–37 (×10³/μL) |
| Hematocrit | 9,800 (mL) | 24.1 mmHg | 7.5 |
| Total protein | 0.4–1.2 (mg/dl) | 6.5–8.5 (g/dl) |
| Albumin | 1.77 | 33 | 8–40 (μL) |
| Total bilirubin | 214 | 69 | 6–40 (μL) |
| AST | 883 | 4,934 | 410 | 120–250 (μL) |
| ALT | 571 | 1222 | 280 | 100–340 (μL) |
| LDH | 334 | 409 | 172 | 8–40 (μL) |
| ALP | 7.5 | 5.6 | 4.9 | 5.6 |
| γ-GTP | 4.0 | 4.9 | 5.1 | 3.7–7.0 (mg/dL) |
| CRP | 0.2–1.2 (mg/dl) | 0.6–1.1 (mg/dl) |
| CK | 20.0 | 107.2 | 67.3 | 8.0–20.0 (mg/dl) |
| Creatinine | 24.03 | 7.3 | 4.65 | < 0.5 (mg/dl) |
| BUN | 329,000 | 3,740 | 3,401 | 33.8–369 (ng/mL) |
| Hemoglobin | 329,000 | 3,740 | 3,401 | 33.8–369 (ng/mL) |
| Hematocrit | 8.9 | 2.5 | 2.0 | 2.0 |
| Platelets | 8,500 | 3,900 | 3,900 | 3,900–9,800 (mL) |
| Na | 176 | 139 | 24.1 mmHg | 139–176 (g/dL) |
| K | 176 | 139 | 24.1 mmHg | 139–176 (g/dL) |
| Ca | 9.3 | 7.7 | 7.3 | 9.2 |
| Glucose | 159 | 107 | 94 | 70–110 (mg/dL) |
| CRP | 24.03 | 7.3 | 4.65 | < 0.5 (mg/dl) |
| Ferritin | 398 | 314 | 314 | 180–320 (mg/dl) |
| sIL-2R | 290.3 | 19.68 | 11.42 | < 0.99 (μg/ml) |
| Coagulation | 1.66 | 0.93 | 0.97 | 0.85–1.15 |
| PT-INR | 48.7 | 28.5 | 28.9 | 24.3–38.9 (sec) |
| APTT | 136 | 134 | 139 | 147 |
| fibrinogen | 20.0 | 44.9 | 51–71 (g/dL) |
| D-dimer | 0.9–1.1 (mg/dl) | 0.6–1.1 (mg/dl) |
| Cytokine | 0.9–1.1 (mg/dl) | 0.6–1.1 (mg/dl) |
| IL-1β | 467 | 44 | 4.40 | < 211 (pg/ml) |
| IL-2 | 2510 | 4,440 | 4,440 | 4,440–5,100 (pg/ml) |
| IL-6 | 2510 | 4,440 | 4,440 | 4,440–5,100 (pg/ml) |
| IL-10 | 2510 | 4,440 | 4,440 | 4,440–5,100 (pg/ml) |
| IL-18 | 2510 | 4,440 | 4,440 | 4,440–5,100 (pg/ml) |
| TNF-α | 47.7 | 8.2 | 8.2 | 8.2 |
| STNFR-1 | 15,400 | 434–930 (pg/ml) |
| STNFR-2 | 434–930 (pg/ml) |
| INF-γ | 15,400 | 434–930 (pg/ml) |
| INF-γ | 15,400 | 434–930 (pg/ml) |

Laboratory parameters including CK, CRP, and ferritin deteriorated on day 6. Thrombocytopenia and anemia occurred afterwards. The levels of CK, Cr, ferritin, and D-dimer markedly improved on day 16 and around day 30. The levels of most cytokines except for IL-18 decreased.

γ-GTP = γ-glutamyltransferase, ALP = alkaline phosphatase, ALT = alanine transaminase, AST = aspartate aminotransferase, BUN = blood urea nitrogen, CK = creatine kinase, CRP = C-reactive protein, IL = interleukin, INF-γ = interferon-γ, LDH = lactate dehydrogenase, PT-INR = prothrombin time-international normalized ratio, sIL-2R = soluble interleukin-2 receptor, STNFR = soluble tumor necrosis factor receptor, TNF-α = tumor necrosis factor-α.
he was moved to the intensive care unit (ICU). His cardiac function was normal and the chest X-ray showed no abnormalities except for the known tumor in the right lung field. He was intubated due to acute respiratory failure and continuous hemofiltration (CHDF) was initiated for acute renal failure (Fig. 2). Catecholamine was not needed to keep the blood pressure. All acute events that occurred simultaneously on day 5 were considered to indicate CRS (Grade 4, according to the Common Terminology Criteria for Adverse Events [version 5.0]) induced by ICIs, which would be steroid-resistant, rather than sepsis. Therefore, from the ICU admission day immunosuppressive therapy was strengthened with 2000 mg of mycophenolate mofetil (MMF), which is recommended in various steroid refractory ir-AEs, together with second methylprednisolone pulse therapy. In addition, plasma exchange was performed in order to remove abnormal cytokines and replace coagulation factors with fresh frozen plasma. IVlg therapy followed 6 times of plasma exchange. Blood cultures collected before the administration of antibiotics were predictably negative and sepsis was ruled out at this point. The immunosuppressive therapy and plasma exchange were effective. The patient was extubated 3 days after the intubation. CHDF was switched to intermittent hemodialysis, and he got off hemodialysis on day 29 and was discharged from the ICU. Laboratory parameters including CRP, CK, D-dimer, and ferritin levels improved gradually, and the levels of most cytokines decreased (Table 1). Thrombocytopenia gradually developed and platelet count reached the minimum of 19,000/μL on day 16. Bone marrow biopsy revealed mild hemophagocytosis, but megakaryocyte count was normal. Thrombocytopenia slowly improved, possibly as a result of immunotherapy. Anemia gradually progressed and did not improve conceivably due to renal dysfunction. Additional problems that occurred a few days after the acute deterioration were intractable oral enanthema and diarrhea without abdominal pain. Tests for serum β-D glucan, cytomegalovirus antigenemia, and Clostridium difficile toxin in the ICU were negative. The biopsy of oral mucosa and tongue ruled out pemphigus vulgaris and pemphigoid, suggesting mucosal damage by the ICIs. Oral enanthema improved around day 60. Colonoscopy revealed mildly white colon mucosa, and colon biopsy showed mild lymphocytic inflammation with edema, which was compatible with colitis induced by ICIs. As it was difficult to continue enteral nutrition because of diarrhea, a central venous port was implanted for intravenous hyperalimentation. It was, of course, difficult to administer nivolumab and ipilimumab again due to the fulminant ir-AEs. Multiple tumors slightly enlarged within one month before the administration of the two ICIs, but remained almost the same size for two months after the admission, likely due to the positive effect of the ICIs. The muscle weakness did not improve possibly due to the complication of critical illness. The patient changed hospital for recuperation on day 93.

3. Discussion

We present a case of fulminant CRS induced by ICI combination therapy. Dermatomyositis preceded the CRS and was steroid-resistant. Plasma exchange and immunosuppressive therapy with steroid and MMF gradually improved clinical symptoms and laboratory parameters.

Various ir-AEs including neuromuscular disorders have been reported so far in conjunction with ICI use. Myositis induced by ICIs (irMyositis) is one of the most common neuromuscular adverse events. Most cases of irMyositis can be successfully treated with steroid therapy and MMF gradually improved clinical symptoms and laboratory parameters. Additional plasma exchange and IVlg did not improve muscle weakness. As the rate of fetal myositis is higher in ICI combination therapy than in monotherapy, the effect of

| Ref | Age | Sex | Cancer type | ICI | Interval from first administration of ICI to CRS | First CRS symptoms | HD | Intubation | Complication of other ir-AE | Treatment | Response to treatment for CRS |
|-----|-----|-----|-------------|-----|-----------------------------------|--------------------|----|-------------|---------------------------|-----------|-------------------------------|
| 1   | 25  | M   | HL          | Nivolumab | 6 days                            | High fever         | No | No          | No                        | Supportive care | Good                          |
| 2   | 29  | F   | ASPS        | Nivolumab | 18 days                           | High fever         | No | No          | No                        | Steroid Tocilizumab | Good                          |
| 3   | 43  | M   | Gastric     | Nivolumab | 8 days                            | High fever         | No | No          | Liver Injury             | Steroid MMF | Partial                        |
| 4   | 52  | F   | Lung        | Nivolumab | 10 weeks                          | High fever         | Yes| No          | PF                        | Steroid MMF | Good                          |
| This case | 70  | M   | Renal       | Nivolumab Ipiilimumab | 5 weeks | High fever | Yes | Yes | Myositis Diarrhea | Steroid MMF PE | Good                          |

ASPS = alveolar soft part sarcoma, CRS = cytokine release syndrome, HD = hemodialysis, HL = hodgkin lymphoma, HLH = hemophagocytic lymphohistiocytosis, ICI = immune checkpoint inhibitor, ir-AE = immune-related adverse event, Mg = intravenous immunoglobulin, MMF = mycophenolate mofetil, PE = plasma exchange, PF = purpura fulminans, TM = thrombomodulin, TTP = thrombotic thrombocytopenic purpura.
steroid was limited in the present case possibly because of the combination therapy. Diarrhea due to colitis was another ir-AE which occurred in this case. Frequency of diarrhea and colitis are higher in ICI combination therapy than in monotherapy.\(^{21}\) Gastrointestinal adverse events can occur at any time during treatment with ICIs. The management of diarrhea and colitis is not standardized, but in severe cases, ICIs should be permanently discontinued and immunosuppressive therapy with steroid or infliximab is recommended.\(^{21}\) In the present case, diarrhea did not improve by immunosuppressive therapy including steroid, MMF, and IVlg, inevitably resulting in the implantation of a central venous port. Infectious etiology was ruled out by colonoscopy and examinations for serum β-D glucan, cytomegalovirus antigenemia, and Clostridium difficile toxin.

CRS is known to commonly occur after CAR-T cell therapy.\(^{8}\) The symptoms can vary from mild to severe and include high fever, hypotension, respiratory failure, renal failure, hepatic damage, disseminated intravascular coagulation, and encephalopathy. As the most common initial symptom is high fever, it is often difficult to distinguish CRS from sepsis. Another differential diagnosis is tumor lysis syndrome, which can be diagnosed by laboratory findings. In the present case, several severe symptoms like those mentioned above occurred simultaneously, and blood cultures were negative. These findings strongly supported the diagnosis of CRS.

To the best of our knowledge, there have been only 4 reported cases of CRS after the administration of ICIs (Table 2).\(^{10–13}\) There likely were unreported or missed cases, which might have contributed to the fulminant CRS in our case. Risk factors for CRS after the administration of ICIs are tumor lysis syndrome, which can be diagnosed by laboratory findings. In the present case, several severe symptoms like those mentioned above occurred simultaneously, and blood cultures were negative. These findings strongly supported the diagnosis of CRS.

The risk factors for CRS after the administration of ICIs are unknown and even those for other relatively common ir-AEs post ICI treatment have not yet been elucidated.\(^{2}\) It is considered that high disease burden (the percentage of blast cells in bone marrow) in leukemia is one of the most important risk factors for CRS after CAR-T cell therapy.\(^{8}\) According to this point of view, large size of the tumor that included both primary and metastatic lesions might have contributed to the fulminant CRS in our case.

ICI combination therapy is associated with severe ir-AEs and multiorgan involvement more frequently than monotherapy.\(^{20,23}\) As mentioned above, risk of fatal myositis and higher grade diarrhea is higher in combination therapy. Notably, fatal ir-AEs tend to occur early after ICI treatment and earlier in combination therapy. (Median time from therapy initiation to symptom onset: 14.5 days in combination therapy and 40 days in monotherapy)\(^{22}\) In the present case, dermatomyositis (Grade 3) and CRS (Grade 4) occurred 23 days and 35 days after the first administration of ICIs, which were compatible timing with the previous reports.

In conclusion, dermatomyositis and fulminant CRS occurred after the combination therapy with ICIs. As the initial symptoms of CRS resemble sepsis, it is important to consider CRS as a differential diagnosis and to initiate immunosuppressive therapy early when needed. Due to a possible risk of severe CRS, more careful observation of symptoms may be necessary especially in the early phase if ICI combination therapy is performed for the patients with large tumors. In steroid-resistant cases, early introduction of additional immunosuppressive therapy and plasma exchange can be effective.

**Author contributions**

Writing – original draft: Junichiro Ohira.
Writing – review & editing: Michi Kawamoto, Yoshio Sugino, Nobuo Kohara.

**References**

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64.
2. Postow MA, Sylon R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158–68.
3. Powles T, Albis L, Stachler M, et al. Updated European Association of Urology guidelines recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol 2017;73:311–5.
4. Larkin J, Chiarioli-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.
5. Moreira A, Loquai C, Pföhler C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 2019;106:12–23.
6. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188–95.
7. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1309–18.
8. Shmabukuro-Vornhagen A, Gödel P, Sukhlev E, et al. Cytokine release syndrome. J Immunother Cancer 2018;6:56.
9. Köhler KC, Hassel JC, Heinzerling L, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges 2016;14:662–81.
10. Zhao L, Yang Y, Li W, et al. Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review. Immunotherapy 2018;10:913–7.
11. Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer 2017;64:26642.
12. Oda H, Ishihara M, Miyahara Y, et al. First case of cytokine release syndrome after nivolumab for gastric cancer. Case Rep Oncol 2019;12:147–56.
13. Honjo O, Kubo T, Sugaya F, et al. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab.
therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer 2019;7:97.

[14] Moch H. The WHO/ISUP grading system for renal carcinoma. Pathologe 2016;37:355–60.

[15] National Cancer Institute: the Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

[16] Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714–68.

[17] Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139–48.

[18] Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283–9.

[19] Fellner A, Makranz C, Lotem M, et al. Neurologic complications of immune checkpoint inhibitors. J Neurooncol 2018;137:601–9.

[20] Wang DY, Salem J-E, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018;4:1721–8.

[21] Tandon P, Bourassa-Blanchette S, Bishay K, et al. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. J Immunother 2018;41:101–8.

[22] Xiao X, He X, Li Q, et al. Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: a case report. Clin Cancer Res 2019;25:29–34.

[23] Zhou S, Khanal S, Zhang H. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag 2019;15:211–21.